Here are the 10-K annual reports from Summit Therapeutics Inc. (SMMT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SMMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMMT filings page.
Summit Therapeutics Inc. is a development-stage biopharmaceutical company focused on oncology, built around ivonescimab, a bispecific antibody targeting PD‑1 and VEGF-A. Summit has licensed rights to develop and commercialize ivonescimab across the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa under a collaboration with Akeso.
The company’s lead program is in non-small cell lung cancer, where the Phase III HARMONi trial in EGFR‑mutated patients previously treated with third‑generation EGFR TKIs showed a statistically significant progression‑free survival benefit for ivonescimab plus chemotherapy, with median PFS of 6.8 months versus 4.4 months for chemotherapy alone and a hazard ratio of 0.52. Longer follow‑up in Western patients confirmed a consistent PFS advantage.
Overall survival analyses showed a favorable trend, including in Western and North American subgroups, and supported submission of a Biologics License Application. The FDA has accepted the BLA for ivonescimab plus chemotherapy in this setting and plans a full review ahead of a Prescription Drug User Fee Act goal action date of November 14, 2026. Summit is also running additional Phase III trials in first‑line metastatic NSCLC (HARMONi‑3, HARMONi‑7) and first‑line unresectable metastatic colorectal cancer (HARMONi‑GI3), while Akeso advances multiple Phase II and III studies in other solid tumors. The company funds this strategy through a large upfront license cost, potential milestones and royalties owed to Akeso, and relies on third‑party manufacturing and extensive patent protection for ivonescimab through at least 2039.